Scarica l'app Stockscreener
63.78
1.67%
-0.63
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit - Stock Titan
Mariner LLC Invests $254,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (RYTM) Expected to Announce Earnings on Wednesday - Defense World
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up - simplywall.st
(RYTM) Trading Report - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by LPL Financial LLC - Defense World
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - MSN
Wells Fargo & Company MN Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $74.92 - Defense World
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - The Manila Times
Rare Disease Pioneer Rhythm Pharmaceuticals Unveils Q1 2025 Earnings Date: Key Updates Coming - Stock Titan
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN
Q2 EPS Estimates for RYTM Raised by Needham & Company LLC - Defense World
RYTM FY2027 EPS Estimate Boosted by Needham & Company LLC - Defense World
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com
Wellington Management Group LLP Sells 2,161 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Raymond James Financial Inc. Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus
Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 11.9% Following Analyst Upgrade - Defense World
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN
Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - marketscreener.com
Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com
Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK
Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada
Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus
Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News
Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com
Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com
Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks
Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada
Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus
Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus
1.72%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):